Most people in cancer research already agree on the broad plot: if the Hippo pathway is the cell's "easy there, champ" system, YAP is what happens when that system stops returning your calls. YAP teams up with TEAD in the nucleus and starts pushing genes that help tumors grow, spread, adapt, and generally act like the coworker who mistakes chaos for leadership. That has made YAP-TEAD an attractive drug target for years. Attractive, yes. Easy, absolutely not.
A new Science Translational Medicine paper takes a swing at that problem with a clever screening setup based on phase separation, then lands on an eyebrow-raising hit: cobimetinib, an FDA-approved MEK inhibitor, can also interfere with the YAP-TEAD complex by binding TEAD's lipid pocket and disrupting TEAD palmitoylation (Yang et al., 2026).
Wait, the MEK drug did what now?
Cobimetinib is not new. It is already used in oncology as a MEK inhibitor. The consensus view would be: nice drug, known lane, move along. This paper says not so fast.
The authors built a high-throughput assay using phase separation, which is one of those real cell-biology concepts that sounds like a wellness trend until you realize proteins really do form droplet-like compartments. Here, that trick let the team screen for molecules that disrupt YAP-TEAD. Cobimetinib popped out, and follow-up structural work suggested it binds the TEAD lipid pocket, blocking palmitoylation, a modification TEAD uses to stay functional.
That matters because YAP itself is a slippery target. TEAD is the more "grab-able" partner. If YAP is the loud frontman, TEAD is the venue manager who controls whether the concert happens at all.
The contrarian part: this is exciting, but mouse tumors are undefeated on social media
The flashy headline is that an approved drug may have a second anti-cancer talent. In mouse and xenograft models, cobimetinib suppressed tumor growth driven by hyperactive YAP-TEAD, helped overcome resistance to MEK inhibition, and boosted first-line drugs such as sorafenib and lenvatinib in hepatocellular carcinoma models (Yang et al., 2026).
That is the good news.
The less glamorous truth is that oncology is full of compounds that look heroic in mice and then arrive in humans wearing clown shoes. YAP-TEAD biology is also messy because this pathway is not just a tumor switch. It helps regulate tissue homeostasis, regeneration, mechanics, and interactions with the tumor microenvironment. Shutting it down systemically could help in one cellular neighborhood and cause trouble in another. A 2024 review in Nature Communications makes exactly that point: TEAD inhibition may have broad promise, but predicting whole-body effects is not trivial (Moya and Halder, 2024).
Why people keep chasing YAP anyway
Because YAP keeps showing up where cancer gets annoyingly adaptable.
Reviews over the last few years have tied YAP/TAZ-TEAD activity to proliferation, metastasis, therapy resistance, and microenvironmental remodeling across multiple tumor types (Cunningham and Hansen, 2022; Piccolo et al., 2023; Han et al., 2023). In plainer English: when cancer needs a backup plan, YAP is often already in the room, feet on the desk, pretending it was invited.
That is why this cobimetinib story is interesting beyond the drug itself. It supports the broader idea that TEAD's palmitoylation pocket is a real therapeutic vulnerability, not just a neat structural biology footnote. Other groups have already shown that direct TEAD inhibitors can work in preclinical models, including mesothelioma (Fan et al., 2022; Miller et al., 2024). And by 2025, early clinical proof-of-concept had started to appear for a TEAD inhibitor, VT3989, in refractory solid tumors, especially mesothelioma (YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial, 2025).
So this is not one weird paper wandering in from the wilderness. It is part of a larger shift: the field is moving from "YAP-TEAD would be nice to drug" to "all right, maybe we can actually do this."
Why this paper punches above its weight
The sneaky power of this study is not just that cobimetinib hit TEAD. It is that the screening strategy worked. If phase separation-based screening can reliably expose compounds that disrupt transcriptional machinery people used to call undruggable, that opens a much bigger door.
And yes, there is a delicious irony here. Cancer drug development often spends years inventing new molecules with names that sound like rejected Wi-Fi passwords. This paper suggests an older approved drug may have been hiding a second identity the whole time. Biology loves that kind of plot twist. It is rude, but it is good television.
For patients, the real-world value is still conditional. These findings need replication, better mechanistic mapping, and eventually clinical testing in tumors where YAP-TEAD is truly driving the disease. But if that holds up, this could mean faster repurposing, smarter combinations, and a more credible route to targeting one of cancer's favorite escape hatches.
References
-
Yang R, Hu L, Wang J, et al. Phase separation-based HTS identifies cobimetinib as a YAP-TEAD inhibitor that suppresses hyperactivated YAP-induced cancer progression. Science Translational Medicine. 2026. DOI: 10.1126/scitranslmed.adu0814
-
Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clinical Science (Lond). 2022;136(3):197-222. DOI: 10.1042/CS20201474. PMCID: PMC8819670
-
Piccolo S, Panciera T, Contessotto P, Cordenonsi M. YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nature Cancer. 2023;4:9-26. Article: s43018-022-00473-z
-
Han H, Sung JY, Kim SH, Lee HJ. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nature Reviews Cancer. 2023. DOI: 10.1038/s41568-023-00579-1
-
Moya IM, Halder G. Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer. Nature Communications. 2024. Article: s41467-024-46531-1
-
Fan M, Lu W, Che J, et al. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling. eLife. 2022;11:e78810. DOI: 10.7554/eLife.78810
-
Miller RM, Ma H, Zhao J, et al. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models. Molecular Cancer Therapeutics. 2024. PubMed: 37748190
-
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nature Medicine. 2025. DOI: 10.1038/s41591-025-04029-3
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.